COR - Cencora, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $359.00 DETAILS

Stock News

Bet on 5 Top-Ranked Stocks With Rising P/E

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Jul 23, 2026 05:25 AM • zacks.com

Cencora: Specialty Infrastructure Is Rewriting The Distributor Model

Cencora (COR) is transitioning from a bulk pharmaceutical distributor to a specialty medicines infrastructure provider, targeting higher-margin, service-driven growth. Recent acquisitions of OneOncology and Retina Consultants of America are driving margin expansion, with Q2 adjusted gross profit up 15.7% and margin rising to 4.31%. Management raised FY2026 adjusted EPS guidance to $17.70–$17.90, expects $3B adjusted FCF, and targets 10–14% long-term EPS growth.

Jul 22, 2026 09:41 AM • seekingalpha.com

Is Cencora Inc (COR) Overvalued After 3.9% Rally? GF Value Says Overvalued

On July 16, 2026, Cencora Inc (COR) shares rose 3.9% to a current price of $307.99. This price performance is notable as it sits within a 52-week range of $244.

Jul 16, 2026 01:49 PM • gurufocus.com

Artisan Mid Cap Fund Q2 2026 Performance Review

Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple positions rising more than 100% during the period. During the quarter, we initiated new positions in Entegris, Modine Manufacturing and C.H. Robinson Worldwide.

Jul 15, 2026 09:56 AM • seekingalpha.com

Carillon Eagle Mid Cap Growth Fund Q2 2026 Portfolio Review

Carillon Eagle Mid Cap Growth Fund stocks delivered solid results in the second quarter. Top securities in the quarter were Datadog, Marvell, Vertiv, Teradyne and Macom Technology Solutions. Top securities in the quarter were Datadog, Marvell, Vertiv, Teradyne and Macom Technology Solutions.

Jul 14, 2026 04:53 AM • seekingalpha.com

Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.

Jul 06, 2026 09:09 AM • fool.com

Cencora Announces Date and Time for Third Quarter Fiscal 2026 Earnings Release

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2026 on Wednesday, August 5, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 5, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer Eva C. Boratto, Executive Vice President & Chief.

Jul 01, 2026 12:30 PM • businesswire.com

COR Stock Down Nearly 18% YTD: Should You Buy, Hold or Sell?

COR shares are down 18% YTD, but rising EPS guidance, specialty pharma growth and strategic expansion could make this pullback worth watching.

Jun 18, 2026 09:50 AM • zacks.com

Cencora Launches Enhanced Nucleus Solution for Specialty Practices

COR's enhanced Nucleus platform targets complex specialty medication workflows, with a pilot underway across more than 20 physician practice sites.

Jun 18, 2026 07:36 AM • zacks.com

Bet on 5 Top-Ranked Stocks With Rising P/E for Solid Returns

Rising P/E ratios can signal confidence and momentum. Discover 5 stocks backed by strong earnings growth and upside potential.

Jun 18, 2026 05:00 AM • zacks.com

Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns

The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. TPR, VRT, CLS and COR are some such stocks.

Jun 17, 2026 05:56 AM • zacks.com

Cencora Launches Next-Generation Nucleus® Solution with Multi-Site Pilot Across Specialty Physician Practices

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global pharmaceutical solutions company, today announced a multi-site pilot of its enhanced Nucleus® inventory management solution, designed to help specialty physician practices manage increasingly complex medication workflows with greater efficiency, visibility and control. Developed with input from customer advisory boards and specialty care providers, the updated platform combines redesigned physical infrastructure with software and interface e.

Jun 17, 2026 04:00 AM • businesswire.com

Cencora Announces Samantha Hammock as Chief Human Resources Officer

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that Silvana Battaglia, Executive Vice President and Chief Human Resources Officer (CHRO), has announced she will retire from the company following a distinguished seven-year tenure. She will be succeeded by Samantha (Sam) Hammock, who will join Cencora as Executive Vice President and CHRO, effective July 13, 2026. "During her seven years of leadership, Silvana has made critical, lasting contributions to Cencora durin.

Jun 15, 2026 12:15 PM • businesswire.com

2 Dirt Cheap Healthcare Stocks to Buy With $1,000 Right Now

The shares of both stocks are down so far this year. Stevanato is benefiting from the need for GLP-1 injectables.

Jun 09, 2026 06:45 AM • fool.com

Cencora's Specialty Supply Chain: Where COR's Growth Is Headed

COR bets on MSOs, specialty logistics and AI tools to deepen ties beyond distribution???even as GLP-1 mix and pricing swings cloud results.

Jun 05, 2026 11:16 AM • zacks.com

Cencora (COR) Up 5.7% Since Last Earnings Report: Can It Continue?

Cencora (COR) reported earnings 30 days ago. What's next for the stock?

Jun 05, 2026 08:36 AM • zacks.com

Wall Street Analysts Predict a 33.55% Upside in Cencora (COR): Here's What You Should Know

The mean of analysts' price targets for Cencora (COR) points to a 33.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Jun 05, 2026 06:57 AM • zacks.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR

NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. ("Cencora" or the "Company") (NYSE: COR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Jun 04, 2026 06:00 AM • prnewswire.com (Hide legal announcements)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. (“Cencora” or the “Company”) (NYSE: COR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Jun 02, 2026 12:57 PM • globenewswire.com (Hide legal announcements)

Cencora to Support U.S. Distribution of Kite's CAR T-Cell Therapies

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora today announced an agreement with Kite, a Gilead Company, to support the distribution of Kite's U.S. Food and Drug Administration (FDA)-approved CAR T-cell therapies, Yescarta® (axicabtagene ciloleucel) and Tecartus® (brexucabtagene autoleucel). The collaboration is designed to support efficient access to the cell therapies at the increasing number of authorized treatment centers in the U.S., including health systems and community oncology practices.

Jun 02, 2026 04:00 AM • businesswire.com